BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed Price. Currency in USD
50.12
+0.52 (+1.05%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close49.60
Open49.78
Bid0.00 x 900
Ask0.00 x 1000
Day's Range48.94 - 50.33
52 Week Range44.30 - 70.05
Volume20,409,896
Avg. Volume12,990,620
Market Cap81.819B
Beta (3Y Monthly)1.12
PE Ratio (TTM)57.41
EPS (TTM)0.87
Earnings DateJan 24, 2019
Forward Dividend & Yield1.64 (3.42%)
Ex-Dividend Date2019-01-03
1y Target Est58.42
Trade prices are not sourced from all markets
  • Dealmaking surge confirms the stock market got far too ch...
    CNBC Videos2 days ago

    Dealmaking surge confirms the stock market got far too ch...

    Jim Cramer explains why there's been more merger and acquisition activity in recent months and says it's "just getting started."

  • CNBC7 hours ago

    Cramer's game plan: This week, forecasts are more important than earnings

    CNBC's Jim Cramer looks ahead at a busy week of earnings reports that he says might drive investors crazy. Johnson & Johnson, Comcast and Starbucks will be among the companies issuing quarterly results. "I can't recall a time when the forecast will be more important, certainly much more important than the results," Cramer, host of "Mad Money," told viewers.

  • Should You Load Up on JNJ Stock Before Earnings?
    InvestorPlace10 hours ago

    Should You Load Up on JNJ Stock Before Earnings?

    Shares of Johnson & Johnson (NYSE:JNJ) have not been trading well, unlike the rest of the market. In fact, the JNJ has moved in the exact opposite direction as the market has over the past few several months. While the rest of U.S. stock market was taking a beating in October and November, Johnson & Johnson stock was one of a handful of names that kept on grinding higher. Of course, it helps that JNJ is a well-known blue-chip dividend stock that investors flock to for safety during bouts of volatility. In December though, investors dumped the stock after negative reports about JNJ surfaced. They allege that Johnson & Johnson failed to alert authorities that at times some of its baby powder products contained asbestos, something the company knew for decades. That's a pretty bold allegation, particularly given the vulnerability of its customer. In any regard, J&J was quick to come out in its own defense and even issued a $5 billion buyback plan. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Even sector M&A -- highlighted by Bristol-Myers' (NYSE:BMY) massive $74 billion deal for Celgene (NASDAQ:CELG) -- wasn't enough to give JNJ much of a lift. Although, the price has stabilized. ### Will It Impact Earnings? The question is, will this report impact the company's fiscal fourth-quarter earnings results, which will be released before the open on Tuesday January 22nd? * 7 Companies Apple Should Consider Buying I imagine that management will address the issue from a proactive position during the company's conference call. I expect them to deny these claims and let their legal team do the heavy lifting. All management is looking to do is reassure investors that the company is not in the wrong -- not that it will be the first time it has faced a major issue though. From a quarterly perspective, it doesn't really matter. JNJ is all about building long-term moats and maintaining its place among the healthcare sector. This situation is unlikely to dethrone the company, even if it does cause some short-term waves in the stock price. Remember, many investors are in this for the long term. As it stands, analysts expect $1.95 in earnings per share for the fourth quarter, representing 12.1% growth year-over-year (YoY). That's impressive growth considering that revenue estimates actually call for a 0.1% contraction to $20.17 billion. Also worth pointing out is that earnings estimates haven't really budged even amid these baby powder reports. 30 days and 60 days ago, analysts were looking for $1.95 in earnings per share and 90 days ago they were looking for $1.96 in EPS. Current estimates call for earnings growth of 11.8% this year to $8.16 per share. However, 2019 estimates call for growth of just 5.5% to $8.61 per share. Revenue growth is expected to fall from 6.4% in 2018 to just 1.6% in 2019. In this respect, let's see where management's guidance falls and whether its better or worse than consensus expectations. ### Trading JNJ Stock So what clues do we see from JNJ stock price ahead of earnings? Shares have been consolidating nicely near $128 to $129 per share. It's a surprisingly tight coil for a stock that's been so quickly beaten down. Investors likely felt that $122 was too much of a selloff, but aren't willing to bid the name up too much ahead of an event like earnings and after a damning baby powder report. It's encouraging to see that the declining 21-day moving average did not weigh on the stock price and push it lower. Instead, JNJ stock traded right past it, like it wasn't even there. However, the stock isn't showing any willingness to trade through the 200-day moving average and ~$132 level. Investors who love JNJ for the long-term can justify adding to their position here, some $20 off the highs we saw in December. However, they should also realize that a decline down to the December lows is possible should JNJ disappoint investors next week. Also keep in mind that the market has rallied like mad over the last three weeks. A pause or decline could weigh on JNJ stock, which has largely sat out the rally this month. * 7 Retail Stocks to Buy for the Rise of Menswear From a trading perspective, I would use a close below $128 as my stop-loss. However, because earnings are involved, it's very possible that whatever direction JNJ trades in could be a gap move. On the downside, look to see if its December lows near $122 hold as support. If it can clear and close above $132, bulls may consider buying a Johnson & Johnson stock breakout. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Companies Apple Should Consider Buying * 7 Beaten-Up Housing Stocks Due for a Bounce Back * Take Buffett's Advice: 5 Vanguard Funds to Buy Compare Brokers The post Should You Load Up on JNJ Stock Before Earnings? appeared first on InvestorPlace.

  • Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
    Zacks16 hours ago

    Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY

    Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.

  • Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup
    American City Business Journals18 hours ago

    Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup

    Atlas Venture-backed Kyn Therapeutics hopes to create drugs that reverse the effects of a metabolite called kynurenine, which cancer cells use to suppress the immune system and ward off attacks.

  • Roche's sBLA for Tecentriq-Abraxane Combo Accepted by FDA
    Zacksyesterday

    Roche's sBLA for Tecentriq-Abraxane Combo Accepted by FDA

    Roche's (RHHBY) sBLA for the label expansion of Tecentriq in combination with Abraxane for the initial treatment of NSCLC has been accepted by the FDA.

  • GuruFocus.comyesterday

    The Stable Value Stock Is Built to Weather Market Storms

    It is hard to say anything about McKesson (MCK) that we have not said before -- it is a high-quality business with extremely cheap shares. McKesson stock is not just cheap -- it's incredibly cheap. McKesson, for example, benefited tremendously when billions of dollars worth of branded drugs lost their patents and went generic between 2009 and 2015.

  • What Kind Of Investor Owns Most Of Bristol-Myers Squibb Company (NYSE:BMY)?
    Simply Wall St.yesterday

    What Kind Of Investor Owns Most Of Bristol-Myers Squibb Company (NYSE:BMY)?

    The big shareholder groups in Bristol-Myers Squibb Company (NYSE:BMY) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own Read More...

  • Ligand (LGND) Takes a Hit on Citron's Negative Research Report
    Zacks2 days ago

    Ligand (LGND) Takes a Hit on Citron's Negative Research Report

    Ligand (LGND) plunges as short-seller Citron Research questions the company's business prospects.

  • Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks2 days ago

    Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth

    Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Why Bristol-Myers Squibb Stock Sank By 15.2% in 2018
    Motley Fool2 days ago

    Why Bristol-Myers Squibb Stock Sank By 15.2% in 2018

    Bristol's inability to compete against Merck in front-line lung cancer weighed heavily on its shares last year.

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.

    # Bristol-Myers Squibb Co ### NYSE:BMY View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for BMY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $10.42 billion over the last one-month into ETFs that hold BMY are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. BMY credit default swap spreads are rising towards their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • The Zacks Analyst Blog Highlights: Procter & Gamble, NVIDIA, Bristol-Myers, Deere and Ecolab
    Zacks2 days ago

    The Zacks Analyst Blog Highlights: Procter & Gamble, NVIDIA, Bristol-Myers, Deere and Ecolab

    The Zacks Analyst Blog Highlights: Procter & Gamble, NVIDIA, Bristol-Myers, Deere and Ecolab

  • Citron Says Ligand Has 80% Downside in Explosive Note
    Investopedia2 days ago

    Citron Says Ligand Has 80% Downside in Explosive Note

    Citron Research, the activist short-seller headed by Andrew Left, has dug up some nasty evidence against Ligand Pharmaceuticals Inc. (LGND). In a 23-page report, Citron accused the San Diego-based biopharmaceutical company of misleading investors, adding that its future revenue calculations are a "pipe dream." The short seller then slapped a $35 price target on the stock, implying 80% downside from the report’s publication date. After failing to successfully develop its own drugs, Ligand switched its business model to focus on collecting royalties and milestone payments from compounds and intellectual property that it licenses to other drug developers.

  • Ligand Crashes To Nearly 2-Year Low After Short-Seller Bashes It
    Investor's Business Daily2 days ago

    Ligand Crashes To Nearly 2-Year Low After Short-Seller Bashes It

    Ligand Pharmaceuticals stock crashed to nearly a two-year low Wednesday after short-seller Citron Research slammed the biotech stock for having "80% downside from its current levels."

  • Top Analyst Reports for Procter & Gamble, NVIDIA & Bristol-Myers
    Zacks3 days ago

    Top Analyst Reports for Procter & Gamble, NVIDIA & Bristol-Myers

    Top Analyst Reports for Procter & Gamble, NVIDIA & Bristol-Myers

  • Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line
    American City Business Journals3 days ago

    Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line

    The 17-year-old biotech company, a big player in antibody drug research and development, will focus its cash on a maturing pipeline of experimental drugs while letting go of some longtime employees.

  • Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter
    Investor's Business Daily3 days ago

    Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter

    Incyte stock launched Tuesday after an analyst suggested its portfolio of cancer treatments could net the biotech stock an acquisition offer. Biotech deals have been rampant this month.

  • Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer
    Zacks4 days ago

    Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer

    Bristol-Myers (BMY) gets EU approval for the immuno-oncology combination of Opdivo and low-dose Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced RCC.

  • How an East Bay cancer fighter — once kicked to the curb by Big Pharma — picked up its 4th drug approval
    American City Business Journals4 days ago

    How an East Bay cancer fighter — once kicked to the curb by Big Pharma — picked up its 4th drug approval

    Even in the days after Bristol-Myers Squibb Co. threw an experimental cancer drug back to Exelixis Inc. nearly a decade ago, there were signs of hope: strong signals from a broad trial that tested the drug across nine tumor types. One of those signals was confirmed Monday as the Food and Drug Administration approved that drug — branded as Cabometyx — as one of a handful of options for people with the most common kind of liver cancer. It is the fourth FDA approval of "cabo" for Alameda-based Exelixis (NASDAQ: EXEL), which eight years ago looked on the ropes when Bristol-Myers Squibb (NYSE: BMY) cut loose from a long-term partnership.

  • Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer
    Zacks4 days ago

    Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer

    Exelixis (EXEL) gets FDA approval for Cabometyx tablets for patients with hepatocellular carcinoma (liver cancer), who have been previously treated with Nexavar.

  • Markit4 days ago

    See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.

    # Bristol-Myers Squibb Co ### NYSE:BMY View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for BMY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $15.76 billion over the last one-month into ETFs that hold BMY are among the highest of the last year, but the rate of growth is slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. BMY credit default swap spreads are at their highest levels for the past 3 years, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019
    Zacks4 days ago

    5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019

    Exelixis (EXEL) lead drug, Cabometyx continues to perform well.

  • Bristol-Myers Squibb (BMY) Stock Moves -0.04%: What You Should Know
    Zacks4 days ago

    Bristol-Myers Squibb (BMY) Stock Moves -0.04%: What You Should Know

    In the latest trading session, Bristol-Myers Squibb (BMY) closed at $47.97, marking a -0.04% move from the previous day.